Possibly Swan, but a cap raise was always on the cards after CAR-T platform acquisition and development.
Cap raises are a necessary evil of 'successful' microcap biotechs.
Institutional placement would be the best outcome.
These players will need to know (and believe in) PTX's strategic plan.
If the 'Friendly Dwarf' is involved no doubt we will get a heads up on the value $ raise and at what price.
Ann: Trading Halt, page-14
Add PTX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.1¢ |
Change
-0.002(4.65%) |
Mkt cap ! $33.01M | |||
| Open | High | Low | Value | Volume |
| 4.3¢ | 4.3¢ | 4.0¢ | $31.43K | 775.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 13923 | 4.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.2¢ | 130000 | 2 |
View Market Depth
| Last trade - 15.43pm 10/05/2024 (20 minute delay) ? |
|
|||||
|
Last
4.0¢ |
Change
-0.002 ( 2.44 %) |
||||
| Open | High | Low | Volume | ||
| 4.2¢ | 4.2¢ | 4.0¢ | 286775 | ||
| Last updated 12.33pm 10/05/2024 ? | |||||
| PTX (ASX) Chart |